The drug clearly seems to have activity given CRs in Rituxan-refractory patients. That should have at least some value IMO, even if we assign no value to the PI3K-delta (let's see what ASH update brings here).
I agree. I can hold indefinitely so no big deal to me. If weakness persists, I may consider adding at some point. My position is so small, it's going to take at least a triple for this to be anything meaningful for me.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.